Alaunos Therapeutics Net Income From Continuing Ops Over Time
| TCRT Stock | USD 2.63 0.29 12.39% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Alaunos Therapeutics Performance and Alaunos Therapeutics Correlation. Is there potential for Biotechnology market expansion? Will Alaunos introduce new products? Factors like these will boost the valuation of Alaunos Therapeutics. If investors know Alaunos will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Alaunos Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.30) | Revenue Per Share | Quarterly Revenue Growth 1 | Return On Assets | Return On Equity |
Understanding Alaunos Therapeutics requires distinguishing between market price and book value, where the latter reflects Alaunos's accounting equity. The concept of intrinsic value - what Alaunos Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Alaunos Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Alaunos Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alaunos Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Alaunos Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income From Continuing Ops Analysis
Compare Alaunos Therapeutics and related stocks such as Radiopharm Theranostics, Cyclerion Therapeutics, and Pasithea Therapeutics Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CYCN | (63.6 M) | (63.6 M) | (63.6 M) | (63.6 M) | (63.6 M) | (63.6 M) | (63.6 M) | (93.9 M) | (115.3 M) | (123 M) | (80.7 M) | (51.6 M) | (44.1 M) | (41.1 M) | (3.1 M) | (3.5 M) | (3.7 M) |
| KTTA | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (13.9 M) | (16.7 M) | (13.9 M) | (12.5 M) | (13.1 M) |
| VYNE | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (29.1 M) | (51.4 M) | (73.7 M) | (255.6 M) | (73.3 M) | (33.9 M) | (29.5 M) | (39.8 M) | (35.8 M) | (37.6 M) |
| QNRX | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (2.1 M) | (21.5 M) | (9.4 M) | (8.6 M) | (9 M) | (8.1 M) | (8.5 M) |
| ADXN | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (4.2 M) | (3.1 M) | (3.3 M) | (1.6 M) | (14.8 M) | (12.9 M) | (15.4 M) | (20.8 M) | (10.6 M) | (4.9 M) | (4.4 M) | (4.6 M) |
| PLRZ | (779 K) | (779 K) | (779 K) | (779 K) | (779 K) | (779 K) | (779 K) | (779 K) | (779 K) | (779 K) | (779 K) | (779 K) | (779 K) | (600 K) | (1.5 M) | (1.4 M) | (1.5 M) |
| AIM | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (14.4 M) | (19.1 M) | (19.4 M) | (29 M) | (17.3 M) | (15.6 M) | (16.4 M) |
| XTLB | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (2.1 M) | (3.6 M) | (2.5 M) | (781 K) | 3 M | (1.3 M) | (782 K) | 435 K | (1.3 M) | (2.2 M) | (1 M) | (1.2 M) | (1.2 M) |
| IBO | (654 K) | (654 K) | (654 K) | (654 K) | (654 K) | (654 K) | (654 K) | (654 K) | (654 K) | (654 K) | (7.3 M) | (7.3 M) | (7.3 M) | (4.4 M) | (24.8 M) | (22.3 M) | (21.2 M) |
Alaunos Therapeutics and related stocks such as Radiopharm Theranostics, Cyclerion Therapeutics, and Pasithea Therapeutics Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Alaunos Therapeutics | TCRT |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 2617 Bissonnet Street, |
| Exchange | NASDAQ Exchange |
USD 2.63
Additional Tools for Alaunos Stock Analysis
When running Alaunos Therapeutics' price analysis, check to measure Alaunos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alaunos Therapeutics is operating at the current time. Most of Alaunos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Alaunos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alaunos Therapeutics' price. Additionally, you may evaluate how the addition of Alaunos Therapeutics to your portfolios can decrease your overall portfolio volatility.